Home|Journals|Articles by Year|Audio Abstracts
 

Original Article



IN SILICO PREDICTIVE FOR MODIFICATION OF CHALCONE WITH PYRAZOLE DERIVATIVES AS A NOVEL THERAPEUTIC COMPOUND FOR TARGETED BREAST CANCER TREATMENT

Riska Prasetiawati, Adel Zamri, Melisa Intan Barliana, Muchtaridi Muchtaridi.




Abstract
Cited by 10 Articles

One of the most common triggers of breast cancer is over expression of estrogen receptor alpha (ERα). Long-term therapy of tamoxifen, an ERα antagonist, can reduce patient’s quality of life because of its side effects. In the previous study, 2’,4’-dihydroxy-6-methoxy-3,5-dimethylchalcone (ChalEA) was isolated as an active compound from the Eugenia aquea leaves that is responsible for breast cancer treatment with positive ERα, however, the potency is lower than tamoxifen. The aim of this study is to find the best modified chalcone that binds well with the ERα. Drug design approaches used in this study were Structure-Based Drug Design (Autodock 4.1) and Ligand-Based Drug Design (LiganScout 4.1). Prediction of absorption, distribution and the toxicity parameters was employed using preADMET and Toxtree. Interactions between tamoxifen and ERα were determined and the differences in the binding modes between tamoxifen and chalcones were observed. Modifina3 had pharmacophore fit score value of 76.42% and the molecular docking studies showed lowest free energy binding (∆G) of -11.07 kcal/mol while tamoxifen of -10.15 kcal/mol. Modifina3 had absorption and distribution properties with the percentage HIA of 95.90%, Caco2 of 46.95% and protein plasma binding of 93.55%. Toxicity prediction of Modifina3 was categorized in class III and risk assessment requires compound specific toxicity data. These results suggest that Modifina3 has potency to be novel therapeutic compound for potent ERα inhibitor targeted breast cancer.

Key words: chalcone, Modifina3, molecular docking, pharmacophore modeling, anti breast cancer






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.